BNC Korea
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
BNC Korea makes injectable dermal fillers, botulinum toxin treatments (the active ingredient in wrinkle-relaxing injections), collagen-based tissue supplements, and functional skincare products, all aimed at the medical aesthetics and dermatology market.
Its products are used by clinics and medical professionals, and it also distributes through cosmetics channels. The company spans medical devices, pharmaceuticals, and cosmetics within a single business, and is listed on KOSDAQ, South Korea's tech and small-cap exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Its consolidated subsidiaries separately develop and distribute aesthetic medical devices as well as biotechnology research reagents and testing equipment, broadening the group's product scope beyond injectables.
BNC Korea in five facts
What does BNC Korea do?
BNC Korea makes injectable dermal fillers, botulinum toxin treatments (the active ingredient in wrinkle-relaxing injections), collagen-based tissue supplements, and functional skincare products, all aimed at the medical aesthetics and dermatology market.
Where is BNC Korea listed and in which sector?
BNC Korea (Korean name: 한국비엔씨) trades under KRX code 256840 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is BNC Korea?
Its market capitalisation was US$144.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were BNC Korea's latest annual revenue and operating profit?
For fiscal year 2025, BNC Korea reported revenue of US$72.4M, operating profit of US$1.2M and net income of US$1.5M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 7.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Sep 23
- Cash/in-kind dividend decision
BNC Korea declared a cash dividend of US$0.05 per share.
Dividend · Feb 25 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
BNC Korea reported consolidated results for FY2025: revenue of US$66.6M (+7.4% year on year), operating profit of US$1.13M (−84.7% year on year) and net income of US$1.42M (−84.5% year on year).
Earnings · Feb 25